Zobrazeno 1 - 10
of 39
pro vyhledávání: ''
Autor:
Amy T.Y. Chang, Tony Mok, Frankie Mo, Jacky Y.C. Li, Oscar S.H. Chan, Ki Wang, Catherine Y.H. Wong, Rebecca M.W. Yeung, Kwok Chi Lam, Frankie P. T. Choi
Publikováno v:
Lung Cancer. 142:41-46
Objectives NSCLC patients harboring EGFR mutation invariably developed resistance to EGFR TKI. We postulated that oligoresidual disease (ORD) after initial TKI might harbor resistant clones. This study aimed to test if preemptive local ablative thera
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between
Autor:
Encarnação Teixeira, Sousa Ac, Martins J, Janeiro A, Malveiro S, M. Felizardo, Oliveira Ar, Nogueira F, Maria Carmo-Fonseca, Silveira C
Publikováno v:
Lung Cancer. 139:35-40
Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKI
Autor:
Camille Mehlman, Etienne Giroux Leprieur, Valérie Gounant, Pierre Olivier Schischmanoff, Gaelle Rousseau-Bussac, Thierry Chinet, B. Duchemann, Jean Trédaniel, Cécile Dujon, Nicolas Girard, Jacques Cadranel, Céline Callens, Roger Lacave, Anaïs Pujals, Nathalie Théou-Anton, Hélène Blons, Sylvie Friard
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, Elsevier, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, Elsevier, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
International audience; Objectives: The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC).Mate
Autor:
Jessica A. Hellyer, Sukhmani K. Padda, Joel W. Neal, Millie Das, Heather A. Wakelee, Henning Stehr, Maximilian Diehn, Kavitha Ramchandran
Publikováno v:
Lung Cancer. 134:42-45
Objectives For patients with Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), frontline EGFR-tyrosine kinase inhibitor (TKI) therapy compared to chemotherapy improves outcomes. However, resistance to these agents un
Autor:
Nicole J. Caixeiro, Wei Chua, P. de Souza, Joseph W. Po, David A. Lynch, Victoria J Bray, Alison W S Luk, Therese M. Becker, Yafeng Ma, Tara L. Roberts, Pei N Ding
Publikováno v:
Lung Cancer. 134:187-193
To determine the predictive and prognostic roles of three blood-based biomarkers: circulating tumour DNA (ctDNA), circulating tumour cells (CTC) and carcinoembryonic antigen (CEA), in patients with advanced epidermal growth factor receptor-mutated (E
Autor:
Xiaojuan Zhang, Xuanxuan Zheng, Jinpo Yang, Peng Li, M. Zhang, Xiangtao Yan, Zhiyong Ma, Huijuan Wang, Guowei Zhang
Publikováno v:
Lung Cancer. 128:6-12
Objective: The objective of this study was to investigate whether first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy improves the prognosis of patients with advanced non-sm
Autor:
Alfredo Berruti, William Vermi, Elisa Roca, Vito Amoroso, Daniela Nonnis, Valeria Tovazzi, Salvatore Intagliata, Alice Baggi, Marta Pozzari
Publikováno v:
Lung Cancer. 127:12-18
The onset of a new histology is a resistant mechanism to tyrosine kinase inhibitors (TKI) in lung adenocarcinoma (ADK), but this phenomenon has not yet been fully clarified. We present a pooled analysis of the outcomes of EGFR-mutated ADK patients wi
Autor:
Melania Pintilie, Shingo Sakashita, Ming-Sound Tsao, Ronald Feld, Suzanne Kamel-Reid, Frances A. Shepherd, Pascale Tomasini, C. Mascaux, Catherine Labbé, Kevin Jao, David M. Hwang, Penelope A. Bradbury, Geoffrey Liu, Natasha B. Leighl, Gregorz J. Korpanty
Publikováno v:
Lung Cancer. 123:22-29
Introduction Somatic mutations are becoming increasingly important biomarkers for treatment selection and outcome in patients with non-small-cell lung cancer (NSCLC). The role of multiple somatic mutations in early-stage NSCLC is unclear. Methods Tis